November #65 : Time for T - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Grin and Cast It

City of Love

Down and Out in L.A.

As Cool as Ice

The Secret Life of Syphilis

Easy Rider

Wheel of Misfortune

Raising Lazio

Neg & Pos

Love Connection

Pick Me!

Comic Belief

Daytime Drama

Catching Up With

La Quinceañera de Allgo

Survivor: The Sex Episode

Milestones

A Watched Pot Boils

Herb Of The Month

Staying Syphi-less

Shelf Life

Pure Gene-ius

Chug-A-Bug

Time for T

Delayed Reaction

Comfort Zone

The Alopecia Trail

Commanding Heights

Patriot's Day

Micro Money

11.3.89 Film Noir

Athletic Supporters

S.O.S

Mailbox



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

November 2000

Time for T

by Lark Lands

If your been-there-done-that anti-HIV drug list is longer than the one for your Thanksgiving grocery list, Boston's Cal Cohen, MD, may have some good news. A recent yearlong trial of through-the-med-mill HIVers showed encouraging results with T-20, Hoffmann La Roche and Trimeris' phase II experimental antiretro-viral -- at least when taken with other meds chosen individually based on resistance testing and clinical history. "This first drug in a new class known as fusion inhibitors is exactly what's needed for the many PWAs who need a second chance," Cohen says. In contrast to all current anti-HIV meds that only work after the virus is inside cells, fusion inhibitors block the virus from entering them. (For more on T-20 and its class, see "This Little Drug Went to Market," POZ, May 2000.)

The median number of anti-HIV meds previously taken by trial participants was a whopping 10, and 80 percent had taken at least one drug from each of the three approved antiretroviral drug classes (nukes, NNRTIs and protease inhibitors). More than half of those taking T-20 regimens had at least a one-log (ten-fold) reduction in viral load (considered enough to slow disease progression) and/or reached an undetectable viral load. Although conclusions from the study are hampered by a high dropout rate -- 31 out of 71 original participants quit -- only one-fifth stopped because of a lack of viral effect, and no one because of T-20 toxicity.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    zeze42
    Bay Area - Peninsula
    California


    jimmy807
    San Antonio
    Texas


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.